Jennifer H Jordan1, Ralph B D'Agostino1, Craig A Hamilton1, Sujethra Vasu1, Michael E Hall1, Dalane W Kitzman1, Vinay Thohan1, Julia A Lawrence1, Leslie R Ellis1, Timothy L Lash1, W Gregory Hundley2. 1. From the Departments of Internal Medicine (Section on Cardiovascular Medicine) (J.H.J., S.V., M.E.H., D.W.K., V.T., W.G.H.), Public Health Sciences (R.B.D., T.L.L.), Biomedical Engineering (C.A.H.), Internal Medicine (Hematology and Oncology Section) (J.A.L., L.R.E.), and Radiology (W.G.H.), Wake Forest University School of Medicine, Winston-Salem, NC. 2. From the Departments of Internal Medicine (Section on Cardiovascular Medicine) (J.H.J., S.V., M.E.H., D.W.K., V.T., W.G.H.), Public Health Sciences (R.B.D., T.L.L.), Biomedical Engineering (C.A.H.), Internal Medicine (Hematology and Oncology Section) (J.A.L., L.R.E.), and Radiology (W.G.H.), Wake Forest University School of Medicine, Winston-Salem, NC. ghundley@wakehealth.edu.
Abstract
BACKGROUND: In a murine anthracycline-related cardiotoxicity model, increases in cardiovascular magnetic resonance myocardial contrast-enhanced T1-weighted signal intensity are associated with myocellular injury and decreases with left ventricular ejection fraction. We sought to determine whether T1- and T2-weighted measures of signal intensity associate with decreases in left ventricular ejection fraction in human subjects receiving potentially cardiotoxic chemotherapy. METHODS AND RESULTS: In 65 individuals with breast cancer (n=51) or a hematologic malignancy (n=14), we measured left ventricular volumes, ejection fraction, and contrast-enhanced T1-weighted and T2-weighted signal intensity before and 3 months after initiating potentially cardiotoxic chemotherapy using blinded, unpaired analysis of cardiovascular magnetic resonance images. Participants were aged 51 ± 12 years, of whom 55% received an anthracycline, 38% received a monoclonal antibody, and 6% received an antimicrotubule agent. Overall, left ventricular ejection fraction decreased from 57 ± 6% to 54 ± 7% (P<0.001) because of an increase in end-systolic volume (P<0.05). T1-weighted signal intensities also increased from 14.1 ± 5.1 to 15.9 ± 6.8 (P<0.05), with baseline values trending higher among individuals who received chemotherapy before study enrollment (P=0.06). Changes in T1-weighted signal intensity did not differ within the 17 LV myocardial segments (P=0.97). Myocardial edema quantified from T2-weighted images did not change significantly after 3 months (P=0.70). CONCLUSIONS: Concordant with previous animal studies, cardiovascular magnetic resonance measures of contrast-enhanced T1-weighted signal intensity occur commensurate with small but significant left ventricular ejection fraction declines 3 months after the receipt of potentially cardiotoxic chemotherapy. These data indicate that changes in T1-weighted signal intensity may serve as an early marker of subclinical injury related to the administration of potentially cardiotoxic chemotherapy in human subjects.
BACKGROUND: In a murineanthracycline-related cardiotoxicity model, increases in cardiovascular magnetic resonance myocardial contrast-enhanced T1-weighted signal intensity are associated with myocellular injury and decreases with left ventricular ejection fraction. We sought to determine whether T1- and T2-weighted measures of signal intensity associate with decreases in left ventricular ejection fraction in human subjects receiving potentially cardiotoxic chemotherapy. METHODS AND RESULTS: In 65 individuals with breast cancer (n=51) or a hematologic malignancy (n=14), we measured left ventricular volumes, ejection fraction, and contrast-enhanced T1-weighted and T2-weighted signal intensity before and 3 months after initiating potentially cardiotoxic chemotherapy using blinded, unpaired analysis of cardiovascular magnetic resonance images. Participants were aged 51 ± 12 years, of whom 55% received an anthracycline, 38% received a monoclonal antibody, and 6% received an antimicrotubule agent. Overall, left ventricular ejection fraction decreased from 57 ± 6% to 54 ± 7% (P<0.001) because of an increase in end-systolic volume (P<0.05). T1-weighted signal intensities also increased from 14.1 ± 5.1 to 15.9 ± 6.8 (P<0.05), with baseline values trending higher among individuals who received chemotherapy before study enrollment (P=0.06). Changes in T1-weighted signal intensity did not differ within the 17 LV myocardial segments (P=0.97). Myocardial edema quantified from T2-weighted images did not change significantly after 3 months (P=0.70). CONCLUSIONS: Concordant with previous animal studies, cardiovascular magnetic resonance measures of contrast-enhanced T1-weighted signal intensity occur commensurate with small but significant left ventricular ejection fraction declines 3 months after the receipt of potentially cardiotoxic chemotherapy. These data indicate that changes in T1-weighted signal intensity may serve as an early marker of subclinical injury related to the administration of potentially cardiotoxic chemotherapy in human subjects.
Authors: D Cardinale; M T Sandri; A Martinoni; A Tricca; M Civelli; G Lamantia; S Cinieri; G Martinelli; C M Cipolla; C Fiorentini Journal: J Am Coll Cardiol Date: 2000-08 Impact factor: 24.094
Authors: Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Waren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani Journal: Int J Cardiovasc Imaging Date: 2002-02 Impact factor: 2.357
Authors: R Wassmuth; S Lentzsch; U Erdbruegger; J Schulz-Menger; B Doerken; R Dietz; M G Friedrich Journal: Am Heart J Date: 2001-06 Impact factor: 4.749
Authors: D B Longmore; R H Klipstein; S R Underwood; D N Firmin; G N Hounsfield; M Watanabe; C Bland; K Fox; P A Poole-Wilson; R S Rees Journal: Lancet Date: 1985-06-15 Impact factor: 79.321
Authors: Daniel R Messroghli; Aleksandra Radjenovic; Sebastian Kozerke; David M Higgins; Mohan U Sivananthan; John P Ridgway Journal: Magn Reson Med Date: 2004-07 Impact factor: 4.668
Authors: Giselle C Meléndez; Bunyapon Sukpraphrute; Ralph B D'Agostino; Jennifer H Jordan; Heidi D Klepin; Leslie Ellis; Zanetta Lamar; Sujethra Vasu; Glenn Lesser; Gregory L Burke; Kathryn E Weaver; William O Ntim; W Gregory Hundley Journal: Am J Cardiol Date: 2017-03-22 Impact factor: 2.778
Authors: El-Sayed H Ibrahim; Dhiraj Baruah; Matthew Budde; Jason Rubenstein; Anne Frei; Rachel Schlaak; Elizabeth Gore; Carmen Bergom Journal: Magn Reson Imaging Date: 2020-08-28 Impact factor: 2.546
Authors: Jennifer H Jordan; Sujethra Vasu; Timothy M Morgan; Ralph B D'Agostino; Giselle C Meléndez; Craig A Hamilton; Andrew E Arai; Songtao Liu; Chia-Ying Liu; João A C Lima; David A Bluemke; Gregory L Burke; W Gregory Hundley Journal: Circ Cardiovasc Imaging Date: 2016-08 Impact factor: 7.792